TNM pTx pNx M1 oder pN1-3. C50 C76 C77 C78 C79 C80
Conditions
Interventions
Group 1: Among other things, cooperation agreements are used to transmit the data collected by the attending physicians as part of the treatment due to advanced or metastatic breast cancer. These incl
Sponsors
Universitätsklinikum Würzburg, Frauenklinik und Poliklinik
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Consecutively treated patients with the inclusion criteria: - Advanced or metastatic breast cancer (ICD10 code: C50; C76-C80); Tumor formula: pTx pNx M1 or pN1-3 regardless of T stage and metastasis - Written declaration of consent (e.g. for comparison of cancer registries) - Residence in Bavaria
Exclusion criteria
Exclusion criteria: - <18 years - No advanced or metastatic breast cancer (ICD10 code: C50; C76-C80) (patients without the desired tumor formula: pTx pNx M1 or pN1-3 regardless of T stage and metastasis)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimation of the prevalence of guideline-compliant therapy of advanced / metastatic breast cancer with an eCRF (doctor's questionnaire) when the patient is included. Which consists of the Charlson Comorbidity Index as a standardized measuring instrument, and other questions (in-house developments). | — |
Secondary
| Measure | Time frame |
|---|---|
| Factors influencing the frequency of guideline-compliant therapy of advanced / metastatic breast cancer, influence of guideline-compliant / non-guideline-compliant therapy of advanced / metastatic breast cancer on patient-relevant outcomes, quality of life, needs of patients and relatives, adherence to drug therapy, evaluation of BRE-BY -MED app | — |
Countries
Germany
Contacts
Public ContactMax Müller-Reiter
Universitätsklinikum WürzburgFrauenklinik
Outcome results
None listed